“New Genetic Tests for Breast Cancer Hold Promise”

“The announcements being made on Tuesday, although coincidental in their timing, speak to the surge in competition in genetic risk screening for cancer since 2013, when the Supreme Court invalidated the gene patents that gave Myriad Genetics a monopoly on BRCA testing…
But the issue of who should be tested remains controversial. The effort of the start-up, Color Genomics, to “democratize access to genetic testing,” in the words of the chief executive, Elad Gil, is generating concern among some experts…
[some] experts say that fewer women in the expanded group would be found to have dangerous mutations, raising the overall cost of testing per cancer case prevented. Moreover, expanded testing could result in many more women being told they have mutations that cannot be classified as either dangerous or benign, leaving women in a state of limbo as to whether they have an increased risk of cancer.”

There is a low level of genetics literacy even among doctors, and there is a really interesting problem of making findings not only comprehensible but valuable and actionable for both doctors and patients.

One clap, two clap, three clap, forty?

By clapping more or less, you can signal to us which stories really stand out.